相关实验视频
Updated: Sep 13, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.1K
短程强效P2Y12 基于抑制剂的DAPT与PCI后基于克洛皮多格勒的DAPT:一种倾向匹配的现实世界研究
1School of Medicine, Mae Fah Luang University, Chiang Rai, Thailand. natchanon.kul@gmail.com.
Cardiovascular drugs and therapy
|July 27, 2025
概括
在ACS患者中,与基于克洛皮多格勒的双抗血小板治疗 (DAPT) 相比,强效P2Y12抑制剂的短疗程并没有改善结局. 不良事件的关键因素包括左心室喷射率的减少和残留冠状动脉疾病.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 双重抗血小板治疗 (DAPT) 是急性冠状动脉综合征 (ACS) 患者皮肤穿冠状动脉干预 (PCI) 后的标准.
- 最佳的P2Y12抑制剂疗法,特别是强效药物的持续时间,需要在现实环境中进一步调查.
研究的目的:
- 为了比较1个月强效P2Y12抑制剂 (蒂卡格勒或普拉苏格勒),其次是克洛皮多格雷尔的临床疗效与基于连续的克洛皮多格雷尔的DAPT.
- 评估对接受PCI的ACS患者血栓事件和死亡率的影响.
主要方法:
- 在1117名ACS患者 (2015-2021) 的回顾性,倾向匹配的队列研究中.
- 比较P2Y12抑制剂疗法:一个月的强效药物,然后是克洛皮多格雷尔与连续的基于克洛皮多格雷尔的DAPT.
- 主要结局:结合1年的血栓性再入院或所有原因的死亡率. 安全终点:与出血相关的再入院.
主要成果:
- 在1个月强效P2Y12抑制剂策略和基于克洛皮多格雷尔的DAPT之间,在初级复合结果中没有显著差异.
- 具体的比较 (克洛皮多格勒与提卡格勒,克洛皮多格勒与普拉苏格勒,提卡格勒与普拉苏格勒) 显示,结局没有统计学上显著的差异.
- 减少左心室喷射率 (<40%) 和残留冠状动脉疾病是不良结果的独立预测因素.
结论:
- 在ACS患者中,一个月的蒂卡格雷勒或普拉苏格雷尔疗程,其次是克洛皮多格雷尔,并不优于基于克洛皮多格雷尔的DAPT.
- 对高风险的ACS患者来说,专注于优化复血管化和心力衰竭治疗的管理策略至关重要.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
646
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
646
Coronary Artery Disease V: Interprofessional Care
33
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
33
Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Coronary Artery Disease IV: Preventive Measures
35
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
35
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29

